Wang Dan, Chen Hailan, Luo Yunhao
Department of Cardiology, The First People's Hospital of Shuangliu District (West China Airport Hospital, Sichuan University), Chengdu, People's Republic of China.
Department of Critical Care Medicine, Chengdu First People's Hospital, Chengdu, People's Republic of China.
Int J Gen Med. 2024 Dec 11;17:6047-6052. doi: 10.2147/IJGM.S499182. eCollection 2024.
Despite advancements in the treatment of heart failure (HF) and modest improvements in survival rates over the past few decades, mortality rate remains significantly high. HF not only imposes a significant economic burden on patients' families but also presents a substantial challenge to society at large. Therefore, effective treatment and prevention strategies are crucial. Numerous studies have demonstrated that histamine H2 receptor antagonists (H2RAs) can benefit patients with HF through various mechanisms. These mechanisms encompass promoting sodium and water excretion, vasodilation, enhancing cardiac output, reducing levels of inflammatory cytokines, improving ventricular remodeling, and reducing mortality rate. Additionally, H2RAs exert beneficial effects on typical risk factors and may prevent the onset of HF. This review aims to elucidate the mechanisms underlying the treatment and prevention of HF using H2RAs. For patients requiring either prevention or management of HF, and who concurrently have acid-related diseases, H2RAs may represent a suitable therapeutic option.
尽管在过去几十年中心力衰竭（HF）的治疗取得了进展，生存率也有一定程度的提高，但死亡率仍然显著偏高。HF不仅给患者家庭带来了沉重的经济负担，也给整个社会带来了巨大挑战。因此，有效的治疗和预防策略至关重要。大量研究表明，组胺H2受体拮抗剂（H2RAs）可通过多种机制使HF患者受益。这些机制包括促进钠和水排泄、血管舒张、增加心输出量、降低炎症细胞因子水平、改善心室重塑以及降低死亡率。此外，H2RAs对典型危险因素具有有益作用，可能预防HF的发生。本综述旨在阐明使用H2RAs治疗和预防HF的潜在机制。对于需要预防或管理HF且同时患有酸相关疾病的患者，H2RAs可能是一种合适的治疗选择。
